Document Detail

Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults.
MedLine Citation:
PMID:  23153437     Owner:  NLM     Status:  Publisher    
BACKGROUND: Pneumococcal vaccines based on conserved protein antigens have the potential to offer expanded protection against Streptococcus pneumoniae. OBJECTIVE: This study examined the safety and immunogenicity in adults of three doses of a pneumococcal single-antigen protein vaccine candidate formulated with aluminum hydroxide adjuvant and recombinantly derived, highly detoxified, genetically mutated pneumolysin protein (PlyD1). METHODS: This phase I, randomized, placebo-controlled, observer-blinded, dose-escalating study enrolled adults (18-50 years). In a pilot safety study, participants received a single injection of 10μg PlyD1 and were observed for 24h. Following review of the pilot safety data, participants were randomized (2:1) to receive two injections of PlyD1 at one of three doses or placebo 30 days apart. Assignment of second injection and successive dose cohorts was made after blinded safety reviews after each injection at each dose level. Safety endpoints included rates of solicited injection site reactions, solicited systemic reactions, unsolicited adverse events (AEs), serious AEs (SAEs), and safety laboratory tests. Immunogenicity endpoints included geometric mean concentrations of anti-PlyD1 IgG as determined by ELISA and functional assessment in an in vitro toxin neutralization assay. RESULTS: The study included a total of 100 participants, including 10 in the pilot study and 90 in the randomized study. None of the participants in the pilot study had SAEs, allergic reactions, or other safety concerns. Ninety participants received two doses of or placebo (n=30) or active vaccine candidate at 10 (n=20), 25 (n=20), or 50μg (n=20). No vaccine-related SAE or discontinuation due to an AE occurred. Most solicited reactions were mild and transient. The most frequently reported solicited reactions were pain at the injection site and myalgia. Antigen-specific IgG levels and functional activity showed dose-related increases. When comparing the three dose levels, a plateau effect was observed at the 25μg dose. CONCLUSIONS: All dose levels were safe and immunogenic. Repeat vaccination significantly increased the level of anti-PlyD1 antibodies. Functional antibody activity was demonstrated in sera from vaccinated individuals ( no. NCT01444352).
Thierry Kamtchoua; Monica Bologa; Robert Hopfer; David Neveu; Branda Hu; Xiaohua Sheng; Nicolas Corde; Catherine Pouzet; Gloria Zimmerman; Sanjay Gurunathan
Related Documents :
23764537 - Control of humoral immunity and auto-immunity by the cxcr4/cxcl12 axis in lupus patient...
23901757 - Detection of infectious laryngotracheitis virus antibodies by glycoprotein-specific eli...
24063457 - Trusts warned to boost flu vaccine uptake, or lose share of £500m.
23462527 - Il4r and il13 polymorphic variants and development of antibodies to surface antigen of ...
11457547 - Detection of anthrax vaccine virulence factors by polymerase chain reaction.
20220777 - Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic cd8+ t-cell ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-12
Journal Detail:
Title:  Vaccine     Volume:  -     ISSN:  1873-2518     ISO Abbreviation:  Vaccine     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8406899     Medline TA:  Vaccine     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Elsevier Ltd. All rights reserved.
Covance Clinical Research Unit AG, SPC 327-10, Lettenweg 118, CH-4123 Allschwil, Switzerland. Electronic address:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Lgr5 is a potential marker of colorectal carcinoma stem cells that correlates with patient survival.
Next Document:  Yersinia enterocolitica ghost with msbB mutation provides protection and reduces proinflammatory cyt...